Type 2 Diabetes

Canagliflozin may reduce the risk of major cardiovascular complication, but amputation risk is increased.

Second-line treatment is often initiated without evidence of recommended use of first-line treatment.

Recent meta-analysis conducted to address ideal amount of dietary carbohydrates in the management of T2DM.

By Guest Writer David Kliff, Diabetic Investor: As we were getting ready to disembark the plane when it arrived in Lisbon I asked a long-term consultant to the diabetes industry why he comes to EASD. “I like to come here because what they have here will show up in our country in two years” was his response. Given what we witnessed at EASD there isn’t much to look forward to in 2019.

Philadelphia youth see rise in diagnosis; especially for African Americans, by 70%.

Common osteoarthritis treatment may be beneficial in lowering HbA1c.

Intensive control of blood pressure, glucose, and lipids benefits patients with type 2 diabetes, the long-awaited, large Japan Diabetes Optimal Integrated Treatment Study for 3 Major Risk Factors of Cardiovascular Diseases (J-DOIT3).

The investigational sodium/glucose cotransporter 2 (SGLT2) inhibitor ertugliflozin (Merck), being developed to improve glycemic control in adults with type 2 diabetes, met the primary outcomes in two yearlong phase 3 trials, VERTIS SU and VERTIS SITA2.

New study finds lower occurrence of heart failure in older people with type 2.

Recent published study showed that health care providers may lack the knowledge to diagnose and even treat prediabetes.